CAJ | 학술논문

目的观察特异性环氧合酶-2抑制剂依托昔布和塞来昔布(celebrex)与长春新碱(VCR)、顺铂(DDP)、鬼臼噻吩甙(VM-26)等抗癌药联用对胶质瘤细胞增殖的影响.方法 30 μmol/L依托昔布、100 μmol/L塞来昔布与不同浓度的VCR、DDP、VM-26单用、联用48 h.噻唑蓝(MTT)比色法检测各组抑制率,中效原理和金正均法评价特异性环氧合酶-2抑制剂与各抗癌药联用的效果.结果 30μmol/L依托昔布和100 μmol/L塞来昔布单用对胶质瘤细胞增殖抑制率分别为(40.87±1.88)%和(46.81±2.37)%;不同浓度(1、10、100 mg/L)的VCR、DDP、VM-26单用对胶质瘤细胞增殖均有不同程度的抑制作用;依托昔布和塞来昔布与不同浓度VCR、DDP、VM-26联用组的抑制率均高于各药物单用组,具有协同作用.结论依托昔布和塞来昔布与抗癌药联用后起协同作用,特异性环氧合酶-2抑制剂可作为抗癌药的化疗增敏剂.
목적 관찰특이성배양합매-2억제제의탁석포화새래석포(celebrex)여장춘신감(VCR)、순박(DDP)、귀구새분대(VM-26)등항암약련용대효질류세포증식적영향.방법 30 μmol/L의탁석포、100 μmol/L새래석포여불동농도적VCR、DDP、VM-26단용、련용48 h.새서람(MTT)비색법검측각조억제솔,중효원리화금정균법평개특이성배양합매-2억제제여각항암약련용적효과.결과 30μmol/L의탁석포화100 μmol/L새래석포단용대효질류세포증식억제솔분별위(40.87±1.88)%화(46.81±2.37)%;불동농도(1、10、100 mg/L)적VCR、DDP、VM-26단용대효질류세포증식균유불동정도적억제작용;의탁석포화새래석포여불동농도VCR、DDP、VM-26련용조적억제솔균고우각약물단용조,구유협동작용.결론 의탁석포화새래석포여항암약련용후기협동작용,특이성배양합매-2억제제가작위항암약적화료증민제.
Objective To study the effects of two specific cyclooxygenase-2 inhibitors, etocoxib and celecoxib, combined with chemotherapeutic drugs vincristine (VCR), diamminedichloroplatinum (DDP) and vumon (VP-26) on glioma cell line U251, and to evaluate whether the specific cyclooxygen-ase-2 inhibitors can be used as a synergetic agent in glioma chemotherapy. Methods The human glioma cell line U251 MG was cutured for 48 h with etocoxib and celecoxib,VCR,DDP or VP-26 alone,or in con-bination with etocoxib/celecoxib and gradient concentrations (1,10,100 mg/L) of VCR, DDP, and VM-26, respectively. MTT assay was performed to detect the cells proliferation. Median-effect principle and Pro-fessor Jin's evaluation methods were applied to evaluate the interaction between the specific cyclooxygen-ase-2 inhibitors and chemotherapeutic agents. Results The growth inhibition rate of U251 MG cells was (40.87±1.88)% and (46.81±2.37)% after treatment with 30 μmol/L etocoxib and 100 μmol/L celecoxib,respectively. The inhibition rate of U251 MG cells treated with VCR,DDP and VP-26 at differ-ent concentrations (1,10, or 100 μmol/L) was (39.83±1.14) %, (45.90±1.27) %, (73.47± 3.0)% ;(38.20±1.65)%, (49.37±1.48)%, (87.52±4.00)% ; (42.84±2.43)%, (53.48± 2.67%, (88.56±2.40) %, respectively. The inhibition rate was relatively higher in the cells treated by the two specific cyclooxygenase inhibitors and the chemotherapeutic agents at different concentrations (P< 0.05), and a synergetic effect existed. Conclusion Both etocoxib and celecoxib suppress human glioma cells in vitro and exert a synergetic role when combined with different concentrations of VCR, DDP, or VM-26,indicating that the two cyclooxygenase inhibitors may be used as a chemotherapeutic sensitizer for chemotherapy of human gliomas.